Physician profile
Vahan S Kassabian
NPI 1730283284
$1,646,315.69
in general payments reported to CMS, 2019-2025
74 companies · $314K in 2025
The $314K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254K · 2020: $138K · 2021: $163K · 2022: $262K · 2023: $270K · 2024: $245K · 2025: $314K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $583K · Travel and Lodging: $112K · Honoraria: $78K · Consulting Fee: $36K · Food and Beverage: $20K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $583,298.80 |
| Travel and Lodging | $111,798.27 |
| Honoraria | $77,593.00 |
| Consulting Fee | $35,524.58 |
| Food and Beverage | $20,103.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $345,538.72 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Astellas Pharma US INC | $248,035.61 | 2019-2025 | Xtandi, Padcev |
| Merck Sharp & Dohme LLC | $220,766.82 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $168,086.77 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $130,056.10 | 2019-2025 | Provenge |
| Urogen Pharma, INC. | $110,398.12 | 2020-2025 | Jelmyto |
| Sumitomo Pharma America, INC. | $98,229.38 | 2023-2025 | Orgovyx, Gemtesa |
| Astrazeneca Pharmaceuticals Lp | $78,185.16 | 2019-2025 | Lynparza, Imfinzi |
| Pfizer INC. | $44,496.42 | 2019-2025 | |
| Sn Holdings, LLC | $42,530.09 | 2021-2024 | |
| Myovant Sciences INC. | $38,531.58 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $37,475.36 | 2021-2025 | Pylarify |
| Tolmar Pharmaceuticals, INC. | $16,556.31 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $11,887.18 | 2019-2025 | Adstiladrin |
| Urogpo LLC | $11,475.82 | 2019-2020 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $9,076.08 | 2025 | |
| Janssen Scientific Affairs, LLC | $7,697.61 | 2019-2024 | Akeega, Erleada |
| Clovis Oncology, INC. | $6,113.17 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $5,370.69 | 2025 | Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $2,358.72 | 2020-2023 | Opdivo |
| Telix Pharmaceuticals | $1,880.40 | 2023-2024 | Illuccix |
| Medtronic, INC. | $1,468.19 | 2021-2024 | Interstim |
| Edap Technomed INC | $951.29 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $824.08 | 2019-2024 | Xiaflex, Aveed |
| Novartis Pharmaceuticals Corporation | $779.57 | 2020-2025 | |
| Angiodynamics, INC. | $730.03 | 2019-2024 | Nanoknife |
| Teleflex LLC | $705.54 | 2021-2024 | Urolift |
| Blue Earth Diagnostics | $630.60 | 2019-2024 | |
| Profound Medical Corp. | $584.37 | 2022-2023 | Tulsa-Pro |
| Boston Scientific Corporation | $571.17 | 2019-2023 | Spaceoar Vue System - 10ml |
| Tempus Ai, INC | $462.37 | 2024-2025 | Xt Cdx |
| Lexington Medical, INC. | $381.96 | 2021 | |
| Baxter Healthcare | $369.92 | 2021-2022 | |
| Accord Healthcare, INC. | $364.64 | 2022-2025 | |
| Coloplast Corp | $240.53 | 2021-2025 | Titan |
| Procept Biorobotics Corporation | $227.63 | 2022-2023 | Aquabeam Robotic System |
| Neotract INC. | $178.11 | 2019-2020 | |
| Ambu INC. | $168.97 | 2021 | |
| Astellas Pharma INC | $140.88 | 2024 | Xtandi |
| Endo USA, INC. | $137.77 | 2024-2025 | Xiaflex, Aveed |
| Myriad Genetic Laboratories, INC. | $136.44 | 2021-2025 | Prolaris |
| Metuchen Pharmaceuticals | $121.10 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $120.64 | 2019-2025 | Magic3 Go Intermittent Urinary Catheter, Bard Urinary Drainage Bag |
| Antares Pharma, INC. | $105.17 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Verity Pharmaceuticals INC. | $99.20 | 2025 | Trelstar |
| Sun Pharmaceutical Industries INC. | $97.61 | 2023-2024 | Yonsa |
| Ethicon US, LLC | $86.54 | 2019 | |
| Canon Medical Systems USA, INC. | $82.11 | 2024 | General Device(S) |
| Laborie Medical Technologies Corp. | $79.42 | 2021-2025 | Endosheath Technology |
| Tolmar, INC. | $75.29 | 2023-2025 | Jatenzo, Eligard |
| Medtronic USA, INC. | $64.80 | 2020 | |
| Convatec INC. | $48.08 | 2025 | |
| Roche Diagnostics Corporation | $46.14 | 2022 | |
| Allergan, INC. | $40.90 | 2019-2020 | |
| Urovant Sciences INC | $40.42 | 2021-2022 | |
| Olympus America INC. | $29.23 | 2022-2025 | Itind System |
| Vertex Pharmaceuticals Incorporated | $28.68 | 2025 | |
| Astellas Pharma Global Development | $28.46 | 2021-2022 | |
| 180 Medical, INC. | $26.62 | 2019 | |
| Innovation Technologies INC | $25.87 | 2025 | Irrisept |
| Pacira Pharmaceuticals Incorporated | $25.53 | 2024 | Iovera, Exparel |
| Rochester Medical Corporation | $24.22 | 2021 | |
| Palette Life Sciences, INC. | $23.40 | 2022 | |
| Travere Therapeutics, INC. | $21.09 | 2019-2022 | |
| Abc Home Medical Supply, INC. | $20.89 | 2024 | |
| Philips North America LLC | $19.77 | 2022 | |
| Abbvie INC. | $19.48 | 2024 | |
| Amgen INC. | $18.06 | 2022 | |
| Eli Lilly and Company | $17.94 | 2023 | Verzenio |
| Gilead Sciences, INC. | $17.72 | 2022 | |
| Halozyme INC | $17.54 | 2023 | |
| Clarus Therapeutics INC. | $17.18 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.92 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,442,032.43 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vahan Kassabian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.